Literature DB >> 15962764

Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor.

K Harashima1, T Akimoto, T Nonaka, K Tsuzuki, N Mitsuhashi, T Nakano.   

Abstract

Until now, there has not been enough information on how androgens or androgen deprivation may influence the response of cancer cells to radiation. In this study, the effect of dihydrotestosterone (DHT) on cellular proliferative activity and radiosensitivity was examined in a hormone-sensitive human prostate cancer cell line, LNCaP. In addition, the study also examined how a heat shock protein 90 (Hsp90) chaperone complex inhibitor modified the effect of DHT on the radiosensitivity of the cells, because binding of the androgen receptor (AR) to Hsp90 is required to maintain the stability and functioning of AR. The hormone-sensitive human prostate cancer cell line, LNCaP, was used. Radicicol was used as one of the known Hsp90 chaperone complex inhibitors, and the cells were incubated in the presence of this compound at a concentration of 500 nM. Cellular radiosensitivity was determined by the clonogenic assay; the changes in the protein expression were examined by Western blotting or immunofluorescence. DHT at a concentration of 1 nM caused enhancement of the proliferative activity and reduction of the radiosensitivity of the cells. Radicicol at a concentration of 500 nM abolished the DHT-induced decrease in cellular radiosensitivity and potentiated the radiation-induced cell killing synergistically. Consistent with the changes in the cellular radiosensitivity, radicicol degraded AR, Raf-1 and HER2/neu via reduced binding of AR to Hsp90, although selective degradation of HER2/neu caused by Herceptin, a monoclonal antibody against HER2, did not affect the cellular radiosensitivity. The results suggest that the Hsp9O chaperone complex may be a potential molecular target for potentiation of radiation-induced cell killing in a hormone-sensitive prostate cancer cell line.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962764     DOI: 10.1080/09553000400029460

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  16 in total

Review 1.  Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

Authors:  Xiangyi Lu; Li Xiao; Luan Wang; Douglas M Ruden
Journal:  Biochem Pharmacol       Date:  2011-11-22       Impact factor: 5.858

Review 2.  Hsp90: a drug target?

Authors:  Jeffrey M Holzbeierlein; Andrew Windsperger; George Vielhauer
Journal:  Curr Oncol Rep       Date:  2010-03       Impact factor: 5.075

3.  Down-regulation of heat shock protein HSP90ab1 in radiation-damaged lung cells other than mast cells.

Authors:  Michael G Haase; Peter Geyer; Guido Fitze; Gustavo B Baretton
Journal:  J Histochem Cytochem       Date:  2014-03-26       Impact factor: 2.479

4.  B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer.

Authors:  Vinita Singh-Gupta; Sanjeev Banerjee; Christopher K Yunker; Joseph T Rakowski; Michael C Joiner; Andre A Konski; Fazlul H Sarkar; Gilda G Hillman
Journal:  Cancer Lett       Date:  2011-12-09       Impact factor: 8.679

5.  C1206, a novel curcumin derivative, potently inhibits Hsp90 and human chronic myeloid leukemia cells in vitro.

Authors:  Ying-Juan Fan; Yi-Xiang Zhou; Lian-Ru Zhang; Qiao-Fa Lin; Ping-Zhang Gao; Fang Cai; Li-Ping Zhu; Bi Liu; Jian-Hua Xu
Journal:  Acta Pharmacol Sin       Date:  2017-12-07       Impact factor: 6.150

6.  Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.

Authors:  L Stingl; T Stühmer; M Chatterjee; M R Jensen; M Flentje; C S Djuzenova
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

Review 7.  Hsp90 inhibitors as promising agents for radiotherapy.

Authors:  Alexander E Kabakov; Vladimir A Kudryavtsev; Vladimir L Gabai
Journal:  J Mol Med (Berl)       Date:  2009-11-28       Impact factor: 4.599

8.  Preclinical evaluation of radiosensitizing activity of Pluronic block copolymers.

Authors:  Reshani H Perera; Ravi Patel; Hanping Wu; Mihika Gangolli; Bryan Traughber; Nancy Oleinick; Agata A Exner
Journal:  Int J Radiat Biol       Date:  2013-06-03       Impact factor: 2.694

9.  Liposomal encapsulation of deguelin: evidence for enhanced antitumor activity in tobacco carcinogen-induced and oncogenic K-ras-induced lung tumorigenesis.

Authors:  Jong K Woo; Dong Soon Choi; Hai T Tran; Brian E Gilbert; Waun Ki Hong; Ho-Young Lee
Journal:  Cancer Prev Res (Phila)       Date:  2009-03-31

Review 10.  Molecular targets for tumor radiosensitization.

Authors:  Philip J Tofilon; Kevin Camphausen
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.